Antiangiogenic Therapies: Going beyond Their Limits ........................................... 31
L. Moserle, G. Jiménez-Valerio, and O. Casanovas

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 ........................................... 42

Précis: mTORC inhibitors decrease MCL-1 translation and cooperate with BCL-2/BCL-XL inhibitors to induce apoptosis and growth arrest in KRAS- and BRAF-mutant colorectal cancer. See commentary, p. 19

Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity ........................................... 53

Précis: Repression of specific miRNAs antagonizes the tumor-suppressive activity of HIF1α in ccRCC tumors by augmenting expression of the oncoprotein HIF2α. See commentary, p. 22

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition ........................................... 61

Précis: Whole-exome and transcriptome sequencing of dabrafenib- and trametinib-resistant melanomas identifies putative mechanisms of acquired resistance to combined RAF/MEK inhibition. See commentary, p. 27

Climbing RAS, the Everest of Oncogenes ........................................... 19
M. Russo, F. Di Nicolantonio, and A. Bardelli
See article, p. 42

miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2α Regulation ........................................... 22
H. Moch and M. Lukamowicz-Rajska
See article, p. 53

Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis ........................................... 25
R.A. Brekken
See article, p. 110

Towards a Unified Model of RAF Inhibitor Resistance ........................................... 27
D.B. Solit and N. Rosen
See articles, p. 61, p. 69, p. 80, p. 94

Cancer Discovery is a bimonthly journal established by the American Association for Cancer Research (AACR) in 2012.

Cancer Discovery Online is the official online platform for Cancer Discovery, providing a platform for selected highlights of recent articles of exceptional significance from the cancer literature.
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition .................. 69
See commentary, p. 27

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma ................. 94
Précis: Whole-exome sequencing identifies diverse mechanisms of resistance to vemurafenib or dabrafenib, many of which result in MAPK pathway reactivation.
See commentary, p. 27

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy .................. 80
Précis: Acquired BRAF inhibitor resistance is driven by heterogeneous genetic alterations that promote MAPK reactivation, PI3K–AKT upregulation, and branched clonal evolution.
See commentary, p. 27

Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma ............... 110
Précis: Loss of the matricellular protein SPARC leads to altered stromal remodeling and abnormal neutrophil activity that exacerbate autoimmunity and promote B-cell transformation.
See commentary, p. 25

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:
- NCI Issues Omics Checklist for Tests
- Obinutuzumab Breaks through to FDA Approval
- ICR Expands CanSAR Drug Discovery Platform
- ASCO Forges Ahead with CancerLinQ
- HPV Vaccine Works against Nine Viral Types
- Ibrutinib Approved for Mantle Cell Lymphoma

AC icon indicates Author Choice
For more information please visit http://www.aacrjournals.org
Cancer Discovery 2014;4:OF1-129.

| Updated version | Access the most recent version of this article at: http://cancerdiscovery.aacrjournals.org/content/4/1 |

- **E-mail alerts**: Sign up to receive free email-alerts related to this article or journal.
- **Reprints and Subscriptions**: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
- **Permissions**: To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/4/1. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.